This study is testing a new combination of treatments for elderly patients (70 years or older) who have newly diagnosed Diffuse Large B-Cell Lymphoma (DLBCL), a type of cancer that starts in white blood cells. The study combines two drugs, Mosunetuzumab and Polatuzumab Vedotin, with a chemotherapy regimen called split-dose CHP (Cyclophosphamide, Doxorubicin, Prednisone). Researchers want to see if this combination improves outcomes for patients. Success in this study means achieving a complete response, which is measured up to six months after treatment. The study aims to enroll 31 participants, but its current status is unclear.

Study design

This is a single-arm, Phase 2 study designed to evaluate the treatment in approximately 31 participants.

What's involved

After the first two cycles of treatment, you will have an interim assessment with PET/CT scans and a blood test (minimal residual disease testing). If these results are good, your treatment regimen may be shortened.

Compensation

Not stated in the trial record.

Follow-up

The primary goal of the study, complete response, is measured up to six months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.